Please wait

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Fred Aslan, M.D., Chief Executive Officer of Artiva Biotherapeutics, Inc. (the “Company”), and Neha Krishnamohan, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:

1.
The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2025, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and
2.
The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 6, 2025

IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 6th day of August, 2025.

 

/s/ Fred Aslan, M.D.

 

 

/s/ Neha Krishnamohan

Fred Aslan, M.D.

 

 

Neha Krishnamohan

President and Chief Executive Officer

 

 

Chief Financial Officer and EVP, Corporate

(Principal Executive Officer)

 

 

Development

 

 

 

(Principal Financial Officer and Principal Accounting Officer)

 

“This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Artiva Biotherapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.”